anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compositions for and methods of attenuating and/or preventing ischemia-reperfusion injury (IRI) are provided. One method comprises administering to a patient in need thereof an agent that binds phosphatidylserine (PS) located on cell surfaces, i.e., PS binding agent. Another method comprises administering to an organ transplant recipient a therapeutic composition comprising a PS binding agent. A method of preventing IRI to cells is also provided. The method comprises adding a PS-binding agent to a therapeutic composition used to treat the cells. Further provided is a method of protecting an organ or a tissue susceptible to IRI. The method comprises contacting the organ or tissue with a PS-binding agent. Such an agent may, for example, attenuate IRI in patients with stroke or myocardial infarction, or following surgical operations. PS-binding agents include modified annexin proteins, antibodies against PS molecules, and other anti-PS molecules.
The invention relates to the technical field of health data analysis, in particular to a configuration training method and system of a health data analysis model based on artificial intelligence. Firstly, through reliable data source selection and data quality evaluation, the accuracy and the integrity of data are ensured. Subsequently, using the feature engineering module, useful features are built according to specific scenarios to enhance the expressive power of the model. Then, an applicable machine learning or deep learning model is selected for training, and model performance and generalization capability are improved through super-parameter adjustment and optimization. In the model evaluation stage, the performance of the model is evaluated through the test data set, and further optimization of the model is performed according to the evaluation result. Finally, the results of the health data analysis are presented to the user in an easily understood manner by the results interpretation and visualization module, providing a decision support.
Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
BACKGROUND: Ocular disorders can arise in the advanced stages of chronic kidney disease (CKD) for various reasons, including uraemia, biochemical abnormalities, hypertension and inadequate haemodialysis treatment.
METHODS: We conducted a cross-sectional study at the Pediatric Nephrology Department, both inpatient and outpatient, of from January 2020 to July 2021. The study aimed to identify and compare ophthalmological changes among children at different stages of CKD to assess potential visual threats. A total of 92 children with advanced-stage CKD, aged 5-18 years, meeting the inclusion and exclusion criteria, were included in the study. Comprehensive assessments, including medical history, physical examinations, relevant tests and detailed ophthalmological examinations, were conducted.
RESULTS: The mean age of the participants was 12.1±3.68 years. Most of the children were boys (66%). Twenty-nine patients exhibited impaired visual acuity, children with (6/60-6/24) scores in Snellen's chart Lid oedema and conjunctival pallor were observed in 20.7% and 60.9% of cases, respectively, which were found to statistically significant with advancing CKD stages (p<0.001). Dry eyes were found in 9.8% of CKD stage V patients receiving dialysis (VD) (p=0.003). One patient had a posterior subcapsular cataract, and 7.6% had conjunctival congestion. Patients with conjunctival congestion and hypertensive retinopathy had significantly higher levels of serum phosphate and calcium phosphate product (p<0.001). Hypertensive retinopathy was present in 16.3% of cases, with a significantly higher proportion in the haemodialysis group (93%). Haemodialysis patients exhibited higher blood pressure, lower haemoglobin levels, and a more severe reduction in estimated glomerular filtration rate (p<0.001).
CONCLUSION: This study highlights the significant ocular complications associated with CKD, underscoring the need for regular ophthalmological screenings.
Methods and compositions are disclosed for treating or preventing adverse CNS effects produced by NMDA receptor hypofunction (NRH), including hypofunction induced by NMDA antagonist drugs, and hypofunction occurring as a causative or aggravating factor in schizophrenia. One method of this invention comprises administering an alpha-2 adrenergic (α2) receptor agonist drug along with an NMDA antagonist drug. The NMDA antagonist drug exerts a primary benefit in reducing excitotoxic brain damage, alleviating neuropathic pain, or preventing or avoiding tolerance or addiction to various types of drugs. The α2 agonist drug acts as a secondary or "safener" drug, to prevent the neurotoxic side effects that would be caused by the NMDA antagonist in the absence of the safener drug. Another method disclosed herein involves the use of an α2 agonist drug, by itself, to combat a different and naturally-occurring form of NMDA receptor hypofunction which occurs as a causative or aggravating mechanism in people suffering from schizophrenia. Although α2 agonists are usually not effective in treating long-standing cases of chronic schizophrenia, where pathological changes in the brain have already reached or approached maximal levels, α2 agonists can be administered early in the illness, such as at the first signs of schizophrenic illness, and continuously or intermittently thereafter to prevent the development or worsening of pathological brain changes.
FIELD: medicine. SUBSTANCE: method involves treating abdominal skin with iodine and ethyl alcohol solution, marking incision line and forming linen operation field of rhomboid shape around it. Two sterile sheets are used for building operation window with operation linen reserve being created. Skin is treated in the area of the linen operation window in laser sterilization mode during 10-15 min at 10.6 mcm wavelength in continuous mode with power density of 21-26 W/sq.cm. EFFECT: high quality of operation field preparation. 1 tbl
BACKGROUND & AIMS: Patients with metastatic, treatment-refractory, and relapsed hepatoblastoma (HB) have survival rates of less than 50% due to limited treatment options. To develop new therapeutic strategies for these patients, our laboratory has developed a preclinical testing pipeline. Given that histone deacetylase (HDAC) inhibition has been proposed for HB, we hypothesized that we could find an effective combination treatment strategy utilizing HDAC inhibition.
METHODS: RNA sequencing, microarray, NanoString, and immunohistochemistry data of patient HB samples were analyzed for HDAC class expression. Patient-derived spheroids (PDSp) were used to screen combination chemotherapy with an HDAC inhibitor, panobinostat. Patient-derived xenograft (PDX) mouse models were developed and treated with the combination therapy that showed the highest efficacy in the PDSp drug screen.
RESULTS: HDAC RNA and protein expression were elevated in HB tumors compared to normal livers. Panobinostat (IC50 of 0.013-0.059 μM) showed strong in vitro effects and was associated with lower cell viability than other HDAC inhibitors. PDSp demonstrated the highest level of cell death with combination treatment of vincristine/irinotecan/panobinostat (VIP). All four models responded to VIP therapy with a decrease in tumor size compared to placebo. After 6 weeks of treatment, two models demonstrated necrotic cell death, with lower Ki67 expression, decreased serum alpha fetoprotein and reduced tumor burden compared to paired VI- and placebo-treated groups.
CONCLUSIONS: Utilizing a preclinical HB pipeline, we demonstrate that panobinostat in combination with VI chemotherapy can induce an effective tumor response in models developed from patients with high-risk, relapsed, and treatment-refractory HB.
IMPACT AND IMPLICATIONS: Patients with treatment-refractory hepatoblastoma have limited treatment options with survival rates of less than 50%. Our manuscript demonstrates that combination therapy with vincristine, irinotecan, and panobinostat reduces the size of high-risk, relapsed, and treatment-refractory tumors. With this work we provide preclinical evidence to support utilizing this combination therapy as an arm in future clinical trials.
Neither the 'Desktop Helper (version 10)' will be integrated in the EMR system nor the 'e-learning' will be offered to GPs. However, to prevent attenuation of usual care, GPs will be free to adjust any medication on their own initiative or to use any other aid to decrease inappropriate prescribing in COPD patients.
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia. Comprehensive modification of established AF risk factors combined with dietary interventions and breaking deleterious habits has been shown to reduce AF burden and recurrence. Numerous AF risk factors, such as diabetes, obesity or hypertension can be partially related to dietary and lifestyle choices. Therefore, dietary interventions may have potential as a therapeutic approach in AF. Based on available data, current guidelines recommend alcohol abstinence or reduction to decrease AF symptoms, burden, and progression, and do not indicate the need for caffeine abstention to prevent AF episodes (unless it is a trigger for AF symptoms). Uncertainty persists regarding harms or benefits of other dietary factors including chocolate, fish, salt, polyunsaturated and monounsaturated fatty acids, vitamins, and micronutrients. This article provides a systematic review of the association between AF and both dietary patterns and components. Additionally, it discusses potentially related mechanisms and introduces different strategies to assess patients' nutrition patterns, including mobile health solutions and diet indices. Finally, it highlights the gaps in knowledge requiring future investigation.
Verapamil Hydrochloride Sustained-Release Capsules are a calcium ion influx inhibitor (slow channel blockers or calcium ion antagonists) which exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells.

Normal sinus rhythm is usually not affected by verapamil HCl. However in patients with sick sinus syndrome, verapamil HCl may interfere with sinus node impulse generation and may induce sinus arrest or sinoatrial block. Atrioventricular block can occur in patients without preexisting conduction defects. (See WARNINGS.) Verapamil HCl does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers. Verapamil HCl may shorten the antegrade effective refractory period of accessory bypass tracts. Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil. (See WARNINGS.)

Verapamil HCl has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.
The invention relates to a medical image processing apparatus, a control method thereof, and a storage medium. The information processing apparatus includes an acquisition unit, a specifying unit, a determination unit, a generation unit, and a display control unit. The acquisition unit acquires a three-dimensional image including at least a tubular structure. The specifying unit specifies a first point within the tubular structure and specifies a lesion outside the tubular structure in the three-dimensional image. The determination unit determines whether or not a blood vessel is present in a region between the first point and the lesion based on a signal value of a voxel of the three-dimensional image in the region between the first point and the lesion. The generation unit generates a two-dimensional image of the tubular structure viewed from the first point based on the three-dimensional image. The display control unit displays information indicating a region of a lesion on the two-dimensional image so as to be distinguishable in a result of determining whether or not a blood vessel exists in the region.
This is a prospective, multicenter, randomize, control and non-inferior study. 220 patients with bifurcation lesions will be randomized 1:1 to each group. after the main branch has been treated successfully, and if the side branch's stenosis is more than 70% and can be pre-dilated by POBA (plain old balloon angioplasty) successfully, then randomizing. the patients in the study group will be treated with paclitaxel-eluting coronary artery balloon dilatation catheter (DIOR), while those in the control group will be treated with paclitaxel-eluting balloon (Bingo). Clinical follow-up will be conducted at baseline, operation, hospital discharge, 1 month, 6 months, 9 months and 12 months after operation, and angiographic follow-up will be conducted at 9 months. The primary endpoint is late lumen loss (LLL) in the balloon dilatation coverage area of side branch of at 9 month after operation. The secondary endpoints include device success, clinical success, target lesion failure (TLF), target lesion revascularization (TLR), clinical composite endpoints and imaging endpoints. The information of adverse events, serious adverse events and device defects will be collected during the study.
Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
PURPOSE: A composition for oral administration containing ibuprofen is provided to shield unpleasant taste without throat irritation. CONSTITUTION: A medicinal composition for oral administration contains 5-80 mass% of ibuprofen, 0.01-10 mass% of sucralose and 0.01-2 mass% of grape fruit flavoring agent. The mass ratio of sucralose and grape fruit flavoring agent is 1/0.01~1/1(=100~1). The mass ratio of ibuprofen and sucralose is 1/0.01~1/0.5(=100~2). The composition contains sugar alcohol. A granular agent, oral disintegrated tablet or troches contains the medicinal composition.
Practical nurses in this arm receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
It is intended to provide a novel and efficacious strategy in organ transplantation. Namely, remedies and methods for preventing acute rejection in organ transplantation and improving the prognostic are provided. A remedy for inhibiting rejection in organ transplantation which contain an NF-.kappa.B  decoy compound is provided. The organ transplantation is typified by kidney transplantation. This remedy may further contain an ultrasonic test contrast medium. Also, a remedy for improving the prognostic of organ transplantation is provided. This remedy is administered to the donor organ and thus elevates the transfection efficiency of the NF-.kappa.B decoy compound into the organ by ultrasonication.
The construction of controlled-release formulations improves the sustained-release performance and utilization efficiency of pesticides, which are important aspects in plant protection and environmental chemistry. The current study employs kasugamycin (Kas), which is widely used to control Magnaporthe oryzae, conjugated with carboxyl-functionalized ZnO quantum dots via amide linkages to yield a pH-responsive pesticide delivery system (Kas@ZnO). Physicochemical characterizations indicated the successful preparation of the Kas@ZnO nanoparticles. In vitro drug release assessments indicated that Kas@ZnO exhibited a loading capacity of 21.05% and could effect the controlled release of Kas in an acidic environment, which is beneficial given the unique acidic microenvironment of M. oryzae. Bioactivity assays demonstrated that Kas@ZnO could simultaneously inhibit mycelial growth and spore germination. Additionally, bioactivity tests showed that the control efficacy of Kas@ZnO against rice blast reached 67.43% after 14 days of in vivo spray inoculation, which was higher than that obtained with Kas (55.50%), suggesting improved beneficial effects of Kas@ZnO application over a prolonged duration. Moreover, Kas@ZnO enhanced the activity of defense-related enzymes in rice and upregulated the expression of defense-related genes, such as OsPR2, OsPR3, OsPR5, OsWRKY45, OsLYP6, and OsNAC4. Ultimately, the biosafety assessments revealed that Kas@ZnO did not exert any harmful effects on rice and demonstrated slight toxicity toward zebrafish. These findings indicate that Kas@ZnO can function as a pH-sensitive pesticide delivery system, allowing for targeted release of the pesticide within plant tissues. This technology demonstrates significant potential for eco-friendly plant disease management.
BACKGROUND: Persistent somatoform pain disorder (PSPD) is often the initial diagnosis in patients seeking treatment in psychiatric departments, making it challenging to consider organic nervous system diseases. However, autoimmune encephalitis can present with atypical initial symptoms, leading to misdiagnosis or missed diagnosis. Lumbar puncture, with antibody support, plays a crucial role in diagnosing autoimmune encephalitis.
CASE PRESENTATION: This report describes a 40-year-old male adult patient who was initially diagnosed with persistent somatoform pain disorder in 2022. The patient reported a reduction in pain while resting on his back. There were no fever or relevant medical history. Despite 8 months of symptomatic treatment, the symptoms did not improve. Moreover, the patient developed confusion, gibberish speech, non-cooperation during questioning, and increased frequency and amplitude of upper limb convulsions. Lumbar puncture revealed elevated protein levels and protein-cell dissociation. The autoimmune encephalitis antibody NMDAR (+) was detected, leading to a diagnosis of autoimmune encephalitis (NMDAR).
CONCLUSION: Autoimmune encephalitis (NMDAR), starting with persistent somatoform pain (PSPD), often presents with atypical symptoms and can be easily misdiagnosed. Therefore, it is important to consider the possibility of organic nervous system disease in time, and to test serum or cerebrospinal fluid antibodies to rule out organic nervous system disease after symptomatic treatment of mental disorders is ineffective. This approach facilitates the early diagnosis of autoimmune encephalitis and other underlying organic neurological disorders.
The present invention relates to an image management system, a wearable device, an image management method, and an image management program. The image management system (10) comprises: a wearable device (12) having a camera (48); and an information processing server (16). The information processing server (16) has a server storage unit (100) that stores a captured image received from the wearable device (12). The wearable device (12) or the information processing server (16) has an information organization unit. When determination that the captured image is not a meal image is made by an image determination unit, the information organization unit delates the captured image. When determination that the captured image is a meal image is made by the image determination unit, the server storage unit (100) holds the captured image.
BACKGROUND: The incidence of nausea and vomiting following craniotomy is high, and pericardium 6 (P6; Neiguan) acupoint stimulation is an important strategy for treating postoperative nausea and vomiting (PONV). Here, we aimed to evaluate the efficacy of transcutaneous electrical acupoint stimulation (TEAS) at P6 as an adjunct to antiemetic drugs to prevent PONV after craniotomy.
MATERIALS AND METHODS: This randomized placebo-controlled trial enrolled 120 patients scheduled for craniotomy. The enrolled patients were randomly assigned to a TEAS or sham TEAS group. The incidence of PONV, pain score, and postoperative remedial treatment with antiemetics and analgesics at 0-2, 2-6, and 6-24 h after craniotomy were assessed.
RESULTS: The patient characteristics did not significantly differ between the two groups (P > 0.05). During 0-2 and 6-24 h after craniotomy, the incidence of vomiting was not significantly different between the two groups (P > 0.05). During 2-6 h, the incidence of vomiting was higher in the sham TEAS group than in the TEAS group (29.3 % vs. 14.0 %, P = 0.047). During 0-2 and 2-6 h, the pain scores did not differ significantly between the two groups (P > 0.05). During 6-24 h after craniotomy, the pain score was significantly higher in the sham TEAS group than in the TEAS group (P = 0.001). The degree of nausea and proportion of patients requiring antiemetic drugs were not significantly different between the two groups in each period (P > 0.05).
CONCLUSION: TEAS at P6 may reduce vomiting incidence and pain scores following craniotomy.
An aqueous ophthalmic preparation is described for the treatment of dry and/or irritated eyes. The preparation is comprised of retinol and/or derivatives or precursors thereof, solubilized in water. Certain non-ionic surfactants and propylmethylcellulose are disclosed as solubilizing agents, with propylmethylcellulose also acting as a mucin-like constituent. The vitamin-containing preparation also contains (1) free radical scavenging compounds end (2) compounds capable, in solution, of chelating multivalent metal cations present in human and/or animal external eye tissue or tsar film. The preferred free radical scavenger is mannitol. The preferred chelating agent is EDTA, present in minimal quantities for chelating certain catalytically active metallic ions present at or near the surface of the eye. Also described are tonicity adjusting compositions and an ophthalmic solution buffering system comprising citric acid and citrates.
This longitudinal observational study examines patients with cardiac arrhythmia (such as atrial fibrillation or atrial flutter) who are undergoing a conventional standard therapy in the Department of Cardiology of the Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin. To examine the impact of psychological symptoms such as anxiety, depression, resilience and risk factors (e.g. neuroticism) on cardiac treatment outcomes, patients are evaluated with a standardized psychological assessment including established questionnaires. The baseline observation is performed before the standard treatment of the arrhythmia (e.g. pharmacological treatment or electrophysiological methods). Follow-up observations are made 3 and 6 month after the cardiological intervention.